Spinal Muscular Atrophy Market Is Driven by the Increasing Prevalence of the Disorder, the Availability of New Treatments, and the Increasing Awareness of the Condition | Sanofi F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH.

Spinal muscular atrophy (SMA) is a rare, genetic neuromuscular disorder that affects the motor neurons in the spinal cord, leading to progressive muscle wasting and weakness. It is the leading genetic cause of infant mortality, with an estimated 1 in 10,000 live births affected. SMA is caused by a mutation in the SMN1 gene, which is responsible for producing a protein necessary for the survival of motor neurons in the spinal cord. As these motor neurons die, the muscles that they control become weaker, leading to a progressive loss of strength and mobility.

Download Sample PDF Of This Report:
https://www.globalinsightservices.com/request-sample/GIS26254

Key Trends
Spinal Muscular Atrophy (SMA) is a genetic disorder that affects the motor neurons of the spinal cord and leads to progressive muscle weakness and paralysis. It is one of the leading causes of infant mortality, affecting approximately 1 in 10,000 births. In recent years, there have been tremendous advances in SMA technology, which have improved the lives of those living with SMA. Here are some of the key trends in SMA technology that are helping to improve the lives of those living with SMA.

One of the most important advances in SMA technology is gene therapy. Gene therapy is an experimental treatment that involves introducing a healthy copy of the gene responsible for SMA into the body. This new gene is designed to replace the defective gene that causes the disorder. This new gene is designed to produce the functional protein that is missing in SMA. Several clinical trials have been conducted to assess the efficacy of gene therapy for SMA, and the results have been encouraging.

Another key trend in SMA technology is stem cell therapy. Stem cell therapy is a form of regenerative medicine that involves using stem cells to replace damaged or lost cells in the body. This type of therapy has the potential to restore lost or damaged nerve cells and muscle tissue in those with SMA. Several clinical trials have been conducted to assess the efficacy of stem cell therapy for SMA, and the results have been promising.

Additionally, there has been a trend toward the development of new drug therapies for SMA. The FDA has recently approved several new drugs for the treatment of SMA, including Spinraza, Zolgensma, and Evrysdi. These drugs are designed to help improve muscle strength and function in those with SMA. The drugs work by increasing the levels of functional proteins in the body that are missing in those with SMA.

Finally, there has been an increase in the use of assistive technologies for those with SMA. Assistive technologies are designed to help those with SMA perform everyday activities and improve their quality of life. Examples of assistive technologies include powered wheelchairs, voice recognition software, and robotic arms.

Request Customization:
https://www.globalinsightservices.com/request-customization/GIS26254

Key Drivers
Spinal muscular atrophy (SMA) is a rare neuromuscular disorder that affects the voluntary muscles of the body. It is caused by a genetic mutation that leads to the loss of motor neurons in the spinal cord and brainstem. It is the leading genetic cause of infant death.

The key drivers of the SMA market are the increasing prevalence of the disorder, the availability of new treatments, and the increasing awareness of the condition.

The prevalence of SMA has been increasing over the past few years, due to the improved diagnosis and better management of the condition. According to the Centers for Disease Control and Prevention, the estimated prevalence of SMA in the U.S. is between 1 in 10,000 and 1 in 20,000 live births. The prevalence of SMA is higher in certain ethnic and racial groups, such as African Americans and Hispanics.

The availability of new treatments has been a major driver of the SMA market. Over the past few years, there have been significant advances in the treatment of SMA. These include the development of gene therapy treatments, such as Zolgensma, and the use of small molecules to modulate the disease. Furthermore, emerging therapies such as stem cell therapy and gene editing are being explored as potential treatments for SMA. These therapies have the potential to provide long-term benefit to patients with SMA.

In addition, there has been an increase in awareness of the condition. This has been driven by the efforts of patient advocacy groups, such as Cure SMA, and the increasing media attention on the condition. This has led to an increase in public awareness and understanding of the condition, which has helped to drive the SMA market.

Finally, the increasing investment in SMA research and development has been a key driver of the SMA market. Pharmaceutical companies and other organizations have been investing heavily in SMA research and development, which has led to the development of new treatments and therapies. This has resulted in increased funding for SMA research and development, which has further driven the SMA market.

Market Segmentation
The market can be segmented into drugs, types, treatment, route of administration, and region. By Drugs, the market can be divided into Nusinersen, Onasemnogene Abeparvovec, and Others. By Types, the market can be divided into Werdnig-Hoffmann Disease, Infant SMA, Kugelberg-Welander Disease, and Adult SMA. By Treatment, the market can be divided into Medication, Physical Therapy, Surgery, and Others. By Route of Administration, the market can be divided into Intrathecal, Intraspinal, Subcutaneous, and Others. By region, the market is divided into North America, Europe, Asia-Pacific, and the Rest of the World.

Key Players
The market includes players such as Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Boehringer Ingelheim International GmbH. (Germany), GSK plc (UK), Novartis AG (Switzerland), Biogen (U.S.), Pfizer Inc.(U.S.), Ionis Pharmaceuticals, Inc. (U.S.), Regeneron Pharmaceuticals Inc (U.S.), and Abbott (U.S.).

Procure Complete Report (pdf with Insights, Charts, Tables, and Figures)
https://www.globalinsightservices.com/checkout/single_user/GIS26254

Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700
Website: https://www.globalinsightservices.com/

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

New Report Published by Global Insight Services:
https://www.globalinsightservices.com/reports/hydrogen-projects-database/

This release was published on openPR.